Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CYBN NASDAQ:DAWN NASDAQ:GYRE NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYBNCybin$8.32-1.7%$7.85$4.81▼$13.88$194.78M0.69290,283 shs436,714 shsDAWNDay One Biopharmaceuticals$6.40-1.5%$6.59$6.08▼$16.76$658.86M-1.271.16 million shs1.87 million shsGYREGyre Therapeutics$7.21-2.4%$8.61$6.11▼$19.00$692.87M1.72130,296 shs52,959 shsZVRAZevra Therapeutics$12.07-4.7%$9.54$5.45▼$13.16$692.24M1.97737,476 shs1.20 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYBNCybin-1.65%+8.90%+5.32%+13.20%+2,154.74%DAWNDay One Biopharmaceuticals-1.54%-5.74%-0.16%-6.43%-59.11%GYREGyre Therapeutics-2.44%-3.74%-13.45%-18.81%-52.41%ZVRAZevra Therapeutics-4.66%-3.67%+33.08%+68.81%+83.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYBNCybin3.0962 of 5 stars3.60.00.00.03.80.81.3DAWNDay One Biopharmaceuticals2.1364 of 5 stars3.63.00.00.00.62.50.0GYREGyre Therapeutics0.0296 of 5 stars0.01.00.00.00.60.80.0ZVRAZevra Therapeutics3.2754 of 5 stars3.65.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYBNCybin 3.25Buy$85.00921.63% UpsideDAWNDay One Biopharmaceuticals 3.14Buy$29.00353.13% UpsideGYREGyre Therapeutics 3.00BuyN/AN/AZVRAZevra Therapeutics 3.11Buy$23.7196.47% UpsideCurrent Analyst Ratings BreakdownLatest CYBN, ZVRA, GYRE, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $29.007/8/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.007/2/2025ZVRAZevra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.005/14/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/14/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYBNCybinN/AN/AN/AN/A$10.83 per shareN/ADAWNDay One Biopharmaceuticals$131.16M4.95N/AN/A$4.99 per share1.28GYREGyre Therapeutics$100.64M6.72$0.19 per share37.42$1.05 per share6.87ZVRAZevra Therapeutics$23.61M27.95N/AN/A$0.74 per share16.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYBNCybin-$57.88M-$3.88N/AN/AN/AN/A-37.58%-36.59%N/ADAWNDay One Biopharmaceuticals-$95.50M-$0.71N/AN/AN/A-42.66%-14.98%-13.04%7/29/2025 (Estimated)GYREGyre Therapeutics$12.09M$0.02360.68∞N/A7.20%9.73%7.66%8/12/2025 (Estimated)ZVRAZevra Therapeutics-$105.51M-$1.90N/A60.35N/A-226.78%-201.05%-53.55%8/12/2025 (Estimated)Latest CYBN, ZVRA, GYRE, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GYREGyre Therapeutics$0.03N/AN/AN/A$30.80 millionN/A8/12/2025Q2 2025ZVRAZevra Therapeutics$0.65N/AN/AN/A$22.49 millionN/A7/29/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35N/AN/AN/A$35.55 millionN/A5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYBNCybinN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYBNCybinN/A24.2424.24DAWNDay One BiopharmaceuticalsN/A10.6210.55GYREGyre TherapeuticsN/A3.603.19ZVRAZevra Therapeutics1.463.022.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYBNCybin17.94%DAWNDay One Biopharmaceuticals87.95%GYREGyre Therapeutics23.99%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipCYBNCybin15.00%DAWNDay One Biopharmaceuticals6.20%GYREGyre Therapeutics10.00%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYBNCybin5023.02 million17.96 millionNot OptionableDAWNDay One Biopharmaceuticals60101.36 million95.08 millionOptionableGYREGyre Therapeutics4093.76 million84.38 millionNo DataZVRAZevra Therapeutics2054.68 million53.37 millionOptionableCYBN, ZVRA, GYRE, and DAWN HeadlinesRecent News About These CompaniesZevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)July 18 at 7:30 AM | globenewswire.comQ2 EPS Forecast for Zevra Therapeutics Boosted by AnalystJuly 18 at 2:13 AM | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.July 17 at 9:39 AM | marketbeat.comWilliam Blair Issues Optimistic Forecast for ZVRA EarningsJuly 17 at 2:25 AM | americanbankingnews.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...July 16 at 4:53 PM | finanznachrichten.deAre You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great ChoiceJuly 16 at 1:01 PM | zacks.com5 Small Drug Stocks to Buy Amid Trump's New Tariff ThreatsJuly 16 at 10:05 AM | zacks.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and MetabolismJuly 16 at 8:13 AM | globenewswire.comZevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type CJuly 16 at 7:52 AM | quiverquant.comQZevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?July 16 at 6:20 AM | marketbeat.comQ2 EPS Forecast for Zevra Therapeutics Raised by AnalystJuly 16 at 6:02 AM | marketbeat.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | finance.yahoo.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | zacks.comHere's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)July 15, 2025 | zacks.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by BrokeragesJuly 15, 2025 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Buy" from AnalystsJuly 15, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Raised to Strong-Buy at Wall Street ZenJuly 14, 2025 | americanbankingnews.comCantor Fitzgerald Issues Positive Outlook for ZVRA EarningsJuly 14, 2025 | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $29.00July 13, 2025 | americanbankingnews.comZevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street ZenJuly 12, 2025 | marketbeat.comZevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation ConferenceJuly 11, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYBN, ZVRA, GYRE, and DAWN Company DescriptionsCybin NYSE:CYBN$8.32 -0.14 (-1.65%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$8.36 +0.04 (+0.49%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Day One Biopharmaceuticals NASDAQ:DAWN$6.40 -0.10 (-1.54%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$6.46 +0.06 (+0.94%) As of 07/18/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Gyre Therapeutics NASDAQ:GYRE$7.21 -0.18 (-2.44%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$7.38 +0.17 (+2.36%) As of 07/18/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Zevra Therapeutics NASDAQ:ZVRA$12.07 -0.59 (-4.66%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$11.58 -0.49 (-4.09%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
